Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation
- 12 November 2015
- journal article
- research article
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 33 (3) , 417-433
Abstract
Human interleukin 15 (IL-15) circulates in blood as a stable molecular complex with the soluble IL-15 receptor alpha (sIL-15Rα). This heterodimeric IL-15:sIL-15Rα complex (hetIL-15) shows therapeutic potential by promoting the growth, mobilization and activation of lymphocytes and is currently evaluated in clinical trials. Favorable pharmacokinetic properties are associated with the heterodimeric formation and the glycosylation of hetIL-15, which, however, remains largely uncharacterized. We report the site-specific N- and O-glycosylation of two clinically relevant large-scale preparations of HEK293-derived recombinant human hetIL-15. Intact IL-15 and sIL-15Rα and derived glycans and glycopeptides were separately profiled using multiple LC-MS/MS strategies. IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures. The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied. Mass analysis of intact IL-15 confirmed its N-glycosylation and suggested that Asn79-glycosylation partially prevents Asn77-deamidation. IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. The sialoglycans displayed α2-3- and α2-6-NeuAc-type sialylation. Non-human, potentially immunogenic glycoepitopes (e.g. N-glycolylneuraminic acid and α-galactosylation) were not displayed by hetIL-15. Highly reproducible glycosylation of IL-15 and sIL-15Rα of two batches of hetIL-15 demonstrated consistent manufacturing and purification. In conclusion, we document the heterogeneous and reproducible N- and O-glycosylation of large-scale preparations of the therapeutic candidate hetIL-15. Site-specific mapping of these molecular features is important to evaluate the consistent large-scale production and clinical efficacy of hetIL-15.Keywords
This publication has 71 references indexed in Scilit:
- Mucin-type O-Glycosylation during DevelopmentJournal of Biological Chemistry, 2013
- Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Nature Immunology, 2012
- Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene familyGlycobiology, 2011
- N-Glycans Modulate the Function of Human Corticosteroid-Binding GlobulinMolecular & Cellular Proteomics, 2011
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesBlood, 2011
- Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primatesBlood, 2010
- Safety and immunologic effects of IL-15 administration in nonhuman primatesBlood, 2009
- Effects of glycosylation on the stability of protein pharmaceuticalsJournal of Pharmaceutical Sciences, 2009
- DNA Damage–Induced Bcl-xL Deamidation Is Mediated by NHE-1 Antiport Regulated Intracellular pHPLOS Biology, 2006
- Converting IL-15 to a superagonist by binding to soluble IL-15RαProceedings of the National Academy of Sciences, 2006